177 related articles for article (PubMed ID: 27741010)
41. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Chao YK; Chang HK; Tseng CK; Liu YH; Wen YW
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868287
[TBL] [Abstract][Full Text] [Related]
42. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
43. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
[TBL] [Abstract][Full Text] [Related]
44. The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.
van Rossum PS; Fried DV; Zhang L; Hofstetter WL; van Vulpen M; Meijer GJ; Court LE; Lin SH
J Nucl Med; 2016 May; 57(5):691-700. PubMed ID: 26795288
[TBL] [Abstract][Full Text] [Related]
45. Surveillance of Clinically Complete Responders Using Serial
Valkema MJ; van der Wilk BJ; Eyck BM; Wijnhoven BPL; Spaander MCW; Doukas M; Lagarde SM; Schreurs WMJ; Roef MJ; van Lanschot JJB; Valkema R
J Nucl Med; 2021 Apr; 62(4):486-492. PubMed ID: 32887759
[TBL] [Abstract][Full Text] [Related]
46. Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumor responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma.
Qiu B; Wang D; Yang H; Xie W; Liang Y; Cai P; Chen Z; Liu M; Fu J; Xie C; Liu H
Radiother Oncol; 2016 Nov; 121(2):239-245. PubMed ID: 27793445
[TBL] [Abstract][Full Text] [Related]
47. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS
J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
[TBL] [Abstract][Full Text] [Related]
48. Patient perspectives on repeated MRI and PET/CT examinations during neoadjuvant treatment of esophageal cancer.
Goense L; Borggreve AS; Heethuis SE; van Lier AL; van Hillegersberg R; Mook S; Meijer GJ; van Rossum PSN; Ruurda JP
Br J Radiol; 2018 Jun; 91(1086):20170710. PubMed ID: 29498535
[TBL] [Abstract][Full Text] [Related]
49. Analyzing the post-contrast attenuation of the esophageal wall on routine contrast-enhanced MDCT examination can improve the diagnostic accuracy in response evaluation of the squamous cell esophageal carcinoma to neoadjuvant chemoradiotherapy in comparison with the esophageal wall thickness.
Djuric-Stefanovic A; Jankovic A; Saponjski D; Micev M; Stojanovic-Rundic S; Cosic-Micev M; Pesko P
Abdom Radiol (NY); 2019 May; 44(5):1722-1733. PubMed ID: 30758534
[TBL] [Abstract][Full Text] [Related]
50. Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade.
Djuric-Stefanovic A; Micev M; Stojanovic-Rundic S; Pesko P; Saranovic Dj
Eur J Radiol; 2015 Dec; 84(12):2477-84. PubMed ID: 26467704
[TBL] [Abstract][Full Text] [Related]
51. Radiation field size and dose determine oncologic outcome in esophageal cancer.
Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
[TBL] [Abstract][Full Text] [Related]
52. A Pathological Study of Residual Cancer in the Esophageal Wall Following Neoadjuvant Chemoradiotherapy: Focus on Esophageal Squamous Cell Carcinoma Patients with False Negative Preoperative Endoscopic Biopsies.
Chao YK; Tsai CY; Chang HK; Tseng CK; Liu YH; Yeh CJ
Ann Surg Oncol; 2015 Oct; 22(11):3647-52. PubMed ID: 25672562
[TBL] [Abstract][Full Text] [Related]
53. An analysis of factors affecting the accuracy of endoscopic biopsy after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Chao YK; Wen YW; Chang HK; Tseng CK; Liu YH
Eur J Surg Oncol; 2017 Dec; 43(12):2366-2373. PubMed ID: 29070435
[TBL] [Abstract][Full Text] [Related]
54. Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre.
Saigí M; Oliva M; Aliste L; Calvo M; Hormigo G; Serra Ò; Boladeras A; Farran L; Robles J; Creus G; Paúles MJ; Gornals JB; de Lama E; Borràs JM; Sala N; Galán M
PLoS One; 2017; 12(9):e0184737. PubMed ID: 28931046
[TBL] [Abstract][Full Text] [Related]
55. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer.
Zuccaro G; Rice TW; Goldblum J; Medendorp SV; Becker M; Pimentel R; Gitlin L; Adelstein DJ
Am J Gastroenterol; 1999 Apr; 94(4):906-12. PubMed ID: 10201455
[TBL] [Abstract][Full Text] [Related]
56. Early metabolic response to chemoradiotherapy by interim FDG PET/CT is associated with better overall survival and histological response in esophageal cancers.
Hammoudi N; Hennequin C; Vercellino L; Costantini A; Valverde A; Cattan P; Quéro L
Dig Liver Dis; 2019 Jun; 51(6):887-893. PubMed ID: 30630738
[TBL] [Abstract][Full Text] [Related]
57. Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy.
Taylor Ripley R; Surman DR; Diggs LP; Trepel JB; Lee MJ; Ryan J; Davis JL; Steinberg SM; Hernandez JM; Hoang C; Kenney CM; Bond CD; Kunst TF; Letai A; Schrump DS
BMC Gastroenterol; 2018 Jun; 18(1):94. PubMed ID: 29933761
[TBL] [Abstract][Full Text] [Related]
58. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
[TBL] [Abstract][Full Text] [Related]
59. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma.
Hong D; Lunagomez S; Kim EE; Lee JH; Bresalier RS; Swisher SG; Wu TT; Morris J; Liao Z; Komaki R; Ajani JA
Cancer; 2005 Oct; 104(8):1620-6. PubMed ID: 16118804
[TBL] [Abstract][Full Text] [Related]
60. Can Clinical Response Predict Pathologic Response Following Neoadjuvant Chemoradiation for Esophageal Cancer?
Khaitan PG; Holliday T; Carroll A; Hofstetter WL; Bayley EM; Zhou N; Desale S; Watson TJ
J Gastrointest Surg; 2022 Jul; 26(7):1345-1351. PubMed ID: 35414141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
